Roche's Tarceva and AstraZeneca's own Iressa are the current standard of care in first line treatments of patients with locally advanced or metastatic EGFR+ lung cancer, but Tagrisso looks set to ...

and Roche’s Tarceva (erlotinib). Over time. most targeted cancer drugs have their efficacy limited by the development of resistance mutations. As exon 20 mutated NSCLC is pretty rare the patient ...

and erlotinib (Tarceva; Genentech), an anti-EGFR tyrosine kinase inhibitor (TKI). But the study that led to that recommendation is more than 10 years old, Kong said, “and the landscape for RCC ...

在全球肺癌治疗市场快速扩张的背景下，EGFR 靶向治疗持续引领创新浪潮。随着奥赛康的利厄替尼获批上市、百济神州的 BG-60366 获得临床试验许可以及强生的兰泽替尼联合疗法取得突破，肺癌治疗迎来新的纪元。这些进展为 CXO ...

1月28日，ImmunoMet Therapeutics公布其在研小分子Lixumistat联合吉西他滨（Gemcitabine）和白蛋白结合型紫杉醇（Nab-paclitaxel），作为一线疗法治疗晚期胰腺癌患者的结果。 胰腺癌因发病隐匿，恶性程度极高，预后效果极差，被称为“癌症之王”。近年来，针对胰腺癌的创新疗法不断增多，为胰腺癌治疗提供了新的选择。 近期，在研小分子Lixumistat联合吉 ...

The global cancer therapeutics and biotherapeutics market size was evaluated at USD 194.15 billion in 2024 and is expected to attain USD 440.59 billion by 2034, growing at a CAGR of 8.54% from 2025 to ...